Mariette Kranendonk

Dr. Mariette Kranendonk

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in Nature
Verified
Journal Article
Open access
PDF file
CVC. Vermeulen
C. Vermeulen
MPMarc Pagès-Gallego
Marc Pagès-Gallego
LKL. Kester
L. Kester
MKMariette Kranendonk
Mariette Kranendonk
PWP. Wesseling
P. Wesseling
JRJeroen de Ridder
Jeroen de Ridder
Central nervous system tumours represent one of the most lethal cancer types, particularly among children1. Primary treatment includes neurosurgical resection of the tumour, in which a delicate balance must be struck between maximizing the extent of resection and minimizing risk of neurological damage and comorbidity2,3. However, surgeons have limited knowledge of the precise tumour type prior to surgery. Current standard practice relies on preoperative imaging and intraoperative histological analysis, but these are not always conclusive and occasionally wrong. Using rapid nanopore sequencing, a sparse methylation profile can be obtained during surgery4. Here we developed Sturgeon, a patient-agnostic transfer-learned neural network, to enable molecular subclassification of central nervous system tumours based on such sparse profiles. Sturgeon delivered an accurate diagnosis within 40 minutes after starting sequencing in 45 out of 50 retrospectively sequenced samples (abstaining from diagnosis of the other 5 samples). Furthermore, we demonstrated its applicability in real time during 25 surgeries, achieving a diagnostic turnaround time of less than 90 min. Of these, 18 (72%) diagnoses were correct and 7 did not reach the required confidence threshold. We conclude that machine-learned diagnosis based on low-cost intraoperative sequencing can assist neurosurgical decision-making, potentially preventing neurological comorbidity and avoiding additional surgeries.

5 February 2014 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
MKMariette Kranendonk
Mariette Kranendonk
DKDominique De Kleijn
Dominique De Kleijn
EKEric Kalkhoven
Eric Kalkhoven
DKDanny A Kanhai
Danny A Kanhai
CUCuno Spm Uiterwaal
Cuno Spm Uiterwaal
FVFrank Lj Visseren
Frank Lj Visseren
Alterations in extracellular vesicles (EVs), including exosomes and microparticles, contribute to cardiovascular disease. We hypothesized that obesity could favour enhanced release of EVs from adipose tissue, and thereby contribute to cardiovascular risk via obesity-induced metabolic complications. The objectives of this study were: 1) to investigate the relation between the quantity, distribution and (dys) function of adipose tissue and plasma concentrations of atherothrombotic EV-markers; 2) to determine the relation between these EV-markers and the prevalence of the metabolic syndrome; and 3) to assess the contribution of EV markers to the risk of incident type 2 diabetes.

6 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
CKCezanne Kooij
Cezanne Kooij
CHCaroline Hulsker
Caroline Hulsker
MKMariette Kranendonk
Mariette Kranendonk
JZJózsef Zsiros
József Zsiros
ALAnnemieke S. Littooij
Annemieke S. Littooij
AMAnnelies M.C. Mavinkurve-Groothuis
Annelies M.C. Mavinkurve-Groothuis
Objective: The purpose of this review is to evaluate the outcomes of testis sparing surgery (TSS) and to investigate under which circumstances TSS can be considered a safe treatment option in pediatric patients with testicular tumors. Methods: A database search was performed in Cochrane, Pubmed, and Embase for studies that focused on TSS as treatment for testicular tumors in the pediatric population, excluding reviews and single case reports. Results: Twenty studies, describing the surgical treatment of 777 patients with testicular tumors, were included in the analysis. The majority of pediatric patients with benign germ cell tumors (GCTs) (mean age: 3.7 years) and sex cord-stromal tumors (SCSTs) (mean age: 6.6 years) were treated with TSS, 61.9% and 61.2%, respectively. No cases of testicular atrophy occurred. Four of the benign GCTs, i.e., three teratomas and one epidermoid cyst, recurred. No cases of recurrence were reported in patients with SCSTs. Of the 243 malignant GCTs (mean age: 4.2 years), only one patient had TSS (0.4%). Conclusion: TSS is a safe treatment option for prepubertal patients less than 12 years of age with benign GCTs and low grade SCSTs.

5 January 2026 in Nature Cancer
Verified
Journal Article
Open access
PDF file
NBNils Bessler
Nils Bessler
AWAmber K. L. Wezenaar
Amber K. L. Wezenaar
HAHendrikus C. R. Ariese
Hendrikus C. R. Ariese
CHCelina Honhoff
Celina Honhoff
NDNoëlle Dommann
Noëlle Dommann
ARAnne C. Rios
Anne C. Rios
Diffuse midline glioma (DMG) is a highly aggressive and untreatable pediatric cancer primarily arising in the pontine brainstem region, necessitating the development of representative models for treatment advance. Here we developed an FGF4-driven human brainstem organoid model, which we used to genetically engineer H3.3K27M-altered DMG. We demonstrated that brainstem pontine glial specification is critical for DMG tumorigenesis, yielding infiltrative tumors that recapitulate patient-representative intratumoral heterogeneity. Prolonged GD2 chimeric antigen receptor (CAR) T cell treatment mirrored clinical outcomes and revealed extensive transcriptional heterogeneity, from which both potent effector and dysfunctional CAR T cell populations could be identified. Furthermore, incorporation of myeloid cells generated DMG-specific microglia that reduced treatment efficacy and revealed CAR T cell functional states most vulnerable to microglia-mediated immunosuppression. Thus, we present a representative DMG model offering a months-long experimental window in vitro, which we leveraged to delineate CAR T cell functionality and microglial impact, aiding therapy development for this devastating disease.

9 April 2025 in Neuro-Oncology
Verified
Journal Article
Closed access
MKMariette Kranendonk
Mariette Kranendonk
RHRaoull Hoogendijk
Raoull Hoogendijk
JLJulie A S Lammers
Julie A S Lammers
JLJasper van der Lugt
Jasper van der Lugt
NTNelleke Tolboom
Nelleke Tolboom
SPSabine L A Plasschaert
Sabine L A Plasschaert
Background: Pediatric high-grade central nervous system (pHG-CNS) tumors are the leading cause of childhood cancer-related deaths, partly due to poor response to standard treatments. B7-H3 is reportedly expressed in pHG-CNS tumors, making antigen-targeting therapies, including anti-B7-H3 chimeric antigen receptor T-cell (CAR-T) therapy, promising. However, given substantial inter-tumoral protein expression diversity in CNS tumors, it’s unclear which patients might benefit from these treatments. Therefore, we studied B7-H3 expression in a large set of pHG-CNS tumors. Methods: We retrospectively analyzed 136 pHG-CNS tumors (embryonal tumors (n = 44), high-grade neuroepithelial tumors (n = 4), ependymomas (n = 30),high-grade gliomas (HGGs, n = 58)) from the Princess Máxima Center for Pediatric Oncology. CD276 mRNA (encoding B7-H3) and immunohistochemical (IHC) protein expression of B7-H3 was measured and correlated to clinical-molecular data. Results: Large variability of B7-H3 mRNA and protein expression was observed both between and within tumor types. Many tumors expressed B7-H3, but 30% of diffuse midline glioma H3K27-altered and ependymomas posterior fossa type A showed no or minimal expression. This variability was unrelated to patient age, tumor location, epigenetic subclass, or molecular tumor driver. B7-H3 negative cases were high in tumor cells, ruling out low tumor cell percentage as an explanation for negative staining. Conclusions: Our study of B7-H3-expression in the largest pHG-CNS tumor set to date revealed significant interpatient variability and numerous negative cases. Our results urge for tumor tissue acquisition at enrollment in B7-H3 targeting therapeutic trials (including CAR-T cells) in order to thoroughly assess the value of IHC B7-H3 expression as biomarker and, ultimately, to allow for more tailored therapy.

21 December 2024 in EBioMedicine
Verified
Journal Article
Open access
FWFleur S.A. Wallis
Fleur S.A. Wallis
JBJohn L. Baker-Hernandez
John L. Baker-Hernandez
MTMarc van Tuil
Marc van Tuil
CHClaudia van Hamersveld
Claudia van Hamersveld
MKMarco J. Koudijs
Marco J. Koudijs
LKLennart A. Kester
Lennart A. Kester
With many rare tumour types, acquiring the correct diagnosis is a challenging but crucial process in paediatric oncology. Historically, this is done based on histology and morphology of the disease. However, advances in genome wide profiling techniques such as RNA sequencing now allow the development of molecular classification tools. Here, we present M&M, a pan-paediatric cancer ensemble-based machine learning algorithm tailored towards inclusion of rare tumour types. The RNA-seq based algorithm can classify 52 different tumour types (precision ∼99%, recall ∼80%), plus the underlying 96 tumour subtypes (precision ∼96%, recall ∼70%). For low-confidence classifications, a comparable precision is achieved when including the three highest-scoring labels. We then validated M&M on an internal dataset (precision 99%, recall 76%) and an external dataset from the KidsFirst initiative (precision 98%, recall 77%). Finally, we show that M&M has similar performance as existing disease or domain specific classification algorithms based on RNA sequencing or methylation data. M&M's pan-cancer setup allows for easy clinical implementation, requiring only one classifier for all incoming diagnostic samples, including samples from different tumour stages and treatment statuses. Simultaneously, its performance is comparable to existing tumour- and tissue-specific classifiers. The introduction of an extensive pan-cancer classifier in diagnostics has the potential to increase diagnostic accuracy for many paediatric cancer cases, thereby contributing towards optimal patient survival and quality of life. Financial support was provided by the Foundation Children Cancer Free (KiKa core funding) and Adessium Foundation.